A Future Made in Canada: Moderna Launches the First Domestic mRNA Vaccines

This fall, a new chapter in Canada’s health-care story begins as Moderna’s first Canadian-made COVID-19 mRNA vaccines begin rolling out. 

Just five years ago, Canada was largely dependent on international supply chains for vaccine production—a sharp contrast to our current capabilities. Moderna has since built and certified a state-of-the-art facility in Laval, Quebec, and is now, for the first time, delivering vaccines through a made-in-Canada supply chain and ensuring Canadians receive doses produced at home.

This milestone marks the first Canadian-made mRNA vaccine doses delivered through a domestic supply chain. As supply chains face disruption and global trade becomes even more uncertain, Canada’s new capacity represents more than infrastructure. It embodies a broader truth: health security is inseparable from national and economic security. With this step, Canada is investing in protection, preparedness and prosperity for the long term.

Why mRNA Matters

The COVID-19 pandemic underscored the value of adaptable vaccine platforms like mRNA. With this technology now produced in Canada, local researchers and health systems can play a greater role in advancing its potential.

Unlike traditional vaccine technologies, mRNA can be rapidly updated and manufactured, proving itself to be one of the most powerful tools in the fight against COVID-19 and future viral threats.

By anchoring this production at home, Canada becomes a contributor to the advancement of mRNA technologies. That means Canadian researchers, health agencies and patients can benefit from new breakthroughs with applications that could extend beyond respiratory diseases to improve the outcomes of infectious diseases, rare diseases and cancer.

Why Canada Was the Right Choice

Canada has long championed science, research and innovation, creating an environment where breakthroughs can flourish. It’s a country that brings together world-class scientific expertise, a skilled workforce, an expanding life sciences sector, and a strong and trusted regulatory system that ensures the highest standards of safety and quality. These factors make it a promising environment for biotech investment.

For example, Moderna’s Laval facility provides proximity to leading academic and research institutions and fits into a broader national strategy to build biomanufacturing capacity.

Equally important, Canadians value having access to free public health care and are recognized worldwide for always looking out for one another—principles that continue to guide national investments in preparedness. This sense of collective responsibility makes Canada not only a logical choice for biotech investment, but also a natural home for technologies designed to protect communities.

Supporting Canada’s Innovation Economy

Beyond health access through a domestic supply chain, Moderna is contributing to high-skilled employment, training opportunities and industry–academic collaboration.

For Canadians, it reflects a shift toward building health solutions closer to home.

It also illustrates how private investment, aligned with strategic partnerships with the Government of Canada, can enhance national capacity and support long-term goals tied to economic security, national preparedness and innovation.

Maintaining and expanding the domestic production of critical health technologies may help Canada navigate a changing global environment.

“By producing mRNA vaccines here in Canada, we can help safeguard communities and strengthen national pandemic preparedness,” said Stefan Raos, general manager at Moderna Canada. “The opening of our Laval facility ensures reliable onshore manufacturing and creates the foundation to manufacture the next generation of vaccines right here at home.”

Why Local Matters

The world has learned some hard lessons in recent years. Fragile supply chains, geopolitical tensions and the sheer speed of viral spread exposed the risks of depending on others for urgent medical supplies. By producing vaccines at home, Canada strengthens its resilience.

But the benefits go beyond emergencies. 

A Future Made in Canada

The launch of Moderna’s Laval facility stands as an anchor for the future. By marrying cutting-edge science with homegrown capacity, Canada is investing not only in pandemic preparedness, but in its place in the global life sciences economy.

As production ramps up in 2025, Canadians can look ahead with new confidence: the next time the world faces a health crisis, Canada will not just wait in line—it will lead, prepare and produce at home.

Click here to learn more about Moderna’s Canadian investments and the future of mRNA innovation.